Recombinant Humanized Bispecific antibody against HER2，KN026

Phase 3

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in First-line Treatment of HER2-positive Recurrent or Metastatic Breast Cancer

Drug Information

Target Indication

First-line Treatment of HER2-positive Recurrent or Metastatic Breast Cancer

Clinical Trial

Last updated: 2/3/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

BIO

BIO-RAD LABORATORIES, INC.

Related Pipeline

COVID-19

Anemia in End Stage Renal Disease

Rheumatoid Arthritis

Healthy

Healthy